Table 3.

Study populations demographics, presenting features and outcomes

Patient	Age	Gender	Ethnicity	Myeloma		Previous GFRa	GFR at Presentation	Oligo-anuricb	Hyper-calcaemia	NSAIDc	Presenting FLC Concentration (mg/L)	Interruption to Chemotherapyd	Renal Recovery	Percentage FLC Reduction at Outcomee	Duration of HCO-HD (days)	GFR at 3 monthsf
				Presentation	Type
1	51	Male	Ca	New	IgA K	n/a	11	No	Yes	No	42,000	Yes	No	n/a	27	n/a
2	68	Female	Ca	New	IgG L	n/a	5	No	No	No	1120	Yes	No	n/a	39	n/a
3	58	Male	Ca	New	IgG L	58	13	No	No	No	855	Yes	No	n/a	32	n/a
4	64	Female	Ca	New	IgA L	n/a	5	Yes	Yes	Yes	1740	Yes	No	n/a	5	n/a
5	52	Male	Ca	Relapsing	Free L	23	9	No	No	No	69,430	Yes	No	n/a	29	n/a
6g	59	Male	Ca	New	Free L	n/a	4	No	No	No	26,382	No	Yes	96	14	83
7	68	Female	Ca	New	Free K	30	8	No	No	No	18,500	No	Yes	81	8	45
8	62	Male	AC	MGUS	IgG K	n/a	6	No	No	Yes	1030	No	Yes	83	18	45
9	53	Male	IA	New	IgA K	>60	13	No	No	No	13,500	No	Yes	50	34	48
10	81	Male	Ca	New	IgG L	n/a	7	Yes	No	No	2110	No	Yes	90	29	34
11	61	Male	IA	Relapsing	IgG K	>60	3	No	No	No	2520	No	Yes	60	18	76
12	71	Male	Ca	New	IgA L	49	3	No	No	No	4200	No	Yes	65	22	34
13	46	Male	Ca	New	IgG K	n/a	9	No	No	No	1780	No	Yes	86	26	29
14	64	Male	IA	Relapsing	IgG L	31	9	No	No	No	2530	No	Yes	93	19	37
15	61	Female	Ca	New	Free K	n/a	5	No	No	No	3000	No	Yes	87	45	11h
16	38	Male	Ca	New	Free K	n/a	7	No	No	No	27,000	No	Yes	87	28	27
17	60	Male	Ca	New	IgG K	n/a	12	No	No	No	2254	No	Yes	79	12	67
18	67	Male	Ca	CLL	IgM L	>60	4	No	No	No	2585	No	Yes	82	39	43
19	55	Female	Ca	New	Free K	n/a	8	No	No	No	8076	Yes	Yes	97	105	17h
20	56	Male	Ca	New	IgA L	n/a	6	No	No	No	9918	No	Yes	97	56	27

n/a, not available; Ca, Caucasian; AC, Afro-Caribbean; IA, Indo-Asian; MGUS, monoclonal gammopathy of undetermined significance.

^aGFR if known 3 to 12 mo before presentation.

^bDefined as a urine output of < 500 ml/24 h.

^cNonsteroidal anti-inflammatory drug (NSAID) use preceding presentation with renal failure.

^dInterruption to chemotherapy during the first 6 wk of treatment.

^eFree light chain (FLC) concentration at dialysis independence.

^fGFR at 3 mo from enrollment.

^gPatient 6 did not have a renal biopsy because of low platelets but was treated to protocol; the 19 remaining patients all had cast nephropathy on renal biopsy.

^hThese patients became independent of dialysis after 3 months therefore the GFRs presented were those at 2 wk after the last dialysis session.